Nkarta
Latest round
- Series B
Last raised
- Aug 2019
Total raised
- $44M
Investors
- 9
About Nkarta
Based in California, US, and founded in 2015, Nkarta, Inc. operates as a provider of advanced cell therapies, such as engineered Natural Killer (NK) cells, to improve cancer treatment across diverse patient populations. In March 2024, Nkarta, Inc.9 per share. The firm trades on NAS (NASDAQ) under the ticker symbol NKTX. The company provides a wide range of biotechnological solutions, such as engineered NK cell therapies designed to target and destroy tumor cells efficiently. Additionally, the firm also provides services such as developing robust immunotherapies without genetic alteration.
Who invested in Nkarta
9 investors across 1 round
See all investors in Nkarta
Sign up free to see every VC on the cap table, the rounds they joined, and how much each round raised.
Funding rounds
Series B
Aug 27, 2019
Amount
$44M
Investors
Questions about Nkarta
Who invested in Nkarta?
Nkarta has 9 investors on record across 1 venture round. Sign up free to see every VC on the cap table and the rounds they joined.
How much funding has Nkarta raised?
Nkarta has raised 1 venture round. Sign up free to see how much each round raised and the total.
When did Nkarta last raise money?
Nkarta's most recent round on record is a Series B, in Aug 2019.
What does Nkarta do?
Based in California, US, and founded in 2015, Nkarta, Inc.
Where is Nkarta headquartered?
Nkarta is headquartered in San Francisco, US.
Which VCs invest in companies like Nkarta?
Among active investors with capital left to deploy, Andreessen Horowitz, Founders Fund, Accel and Thrive Capital back healthcare specialists companies at Nkarta's stage. Their profiles are linked below.
VCs backing healthcare specialists startups at Series B
Raising like Nkarta? Find the right VCs.
Capital Atlas matches your startup to active investors by stage, sector and region.